Outlook Therapeutics, Inc. Common Stock

OTLKNASDAQ • USD
ThemeBiotech - Drug Development›Clinical-Stage Platforms
0.61 USD
↘ 0.04 (5.90%)AT CLOSE (11:59 AM EDT)
0.60
↘ 0.01 (1.15%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
0.60
↘ 0.01 (1.15%)
🔴Market: CLOSED

Outlook Therapeutics, Inc. Common Stock (OTLK) is currently trading at $0.60. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Strong Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, exceptional Return on Equity (460.2%) and a bullish Golden Cross on the moving averages.

Technical & fundamental data as of Aug 24, 2026.

Open?$0.62
High?$0.64
Low?$0.59
Prev. Close?$0.65
Volume?14.8M
Avg. Volume?22.4M
VWAP?$0.61
Rel. Volume?0.66x
Bid / Ask
Bid?$0.60 × 2.0K
Ask?$0.60 × 100
Spread?$0.00
Midpoint?$0.60
Valuation & Ratios
Market Cap?148.0M
Shares Out?243.4M
Float?83.0M
Float %?99.9%
P/E Ratio?N/A
P/B Ratio?-14.24
EPS?-$0.20
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Themes
Biotech - Drug Development›Clinical-Stage PlatformsLongevity & Aging›Age-Related Therapeutics
Employees
17
Market Cap
157.1M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.outlooktherapeutics.com
Listed
2016-05-13
Address
111 S. WOOD AVENUE
ISELIN, NJ 08830
Phone: (609) 619-3990
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookStrong Sell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
29
Short Sent.?
34
Piotroski F-Score?2/9Weak
Altman Z-Score?-37.48Distress
Confidence?64%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?24.11%Squeeze Risk
Short Interest?20.0M
Days to Cover?1.1
Free Float83.0M
Avg Daily Volume18.3M
Settlement Date2026-07-31
Financial Health
Current Ratio?0.81Weak
Quick Ratio?0.63Weak
Cash Ratio?0.39Low
Debt/Equity?-1.75Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
S&P
97
-14.24CHEAP▾
P/S?
S&P
97
-138.13CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-4.1CHEAP▾
EV/Sales?
S&P
97
-144.65CHEAP▾
Returns & Efficiency
ROE?
Peers
50
S&P
97
460.2%STRONG▾
ROA?
S&P
3
-182.7%WEAK▾
Cash Flow & Enterprise
FCF?$-56154885
Enterprise Value?$155.0M
Fundamentals ratios updated end of day
MarketsMoversWatchlist